Gain Therapeutics Inc (NAS:GANX)
$ 2.45 -0.05 (-2%) Market Cap: 44.23 Mil Enterprise Value: 33.54 Mil PE Ratio: 0 PB Ratio: 5.10 GF Score: 57/100

Gain Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 28, 2023 / 04:40PM GMT
Release Date Price: $3.19 (-0.62%)
Jason Bouvier
Cantor Fitzgerald, L.P. - Moderator

Good afternoon, everyone. My name is Jason Bouvier, and I'm joined by Matthias Alder, CEO of Gain Therapeutics and also Director. So welcome. I guess we'll just we'll go ahead and get started.

Matthias Alder
Gain Therapeutics, Inc. - CEO & Director

Thanks, Jason.

Jason Bouvier
Cantor Fitzgerald, L.P. - Moderator

Yup. So, I thought we could just open maybe with a brief high-level overview of the company.

Matthias Alder
Gain Therapeutics, Inc. - CEO & Director

Thanks. So, Gain Therapeutics is actually at its core a computational drug discovery company. And the platform that we have allows us to discover novel, differentiated, first-in-class, small molecule therapies across the entire spectrum of therapeutic areas.

A very broad application of the platform have used the platform to generate the entirety of our product pipeline. And the lead program is just about the transition to clinical stage at this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot